American Cancer Society (ACS) Includes Exact Sciences’ Cologuard in Colorectal Cancer Prevention and Early Detection Guidelines.

American Cancer Society (ACS) Includes Exact Sciences’ Cologuard in Colorectal Cancer Prevention and Early Detection Guidelines.

The American Cancer Society (ACS) guidelines include Cologuard in a recommended list of screening options for colorectal cancer. ACS guidelines also reflect the Centers for Medicare and Medicaid Services assessment that Cologuard be performed every three years for patients 50 and older who do not have symptoms of colorectal cancer and who do not have an increased risk of colorectal cancer. Medicare covers Cologuard for individuals’ age 50-85 fitting these criteria once every three years at no cost to patients.

Available by prescription only, Cologuard is the first and only FDA approved noninvasive stool DNA screening test for colorectal cancer that can be performed in the privacy of individual’s own home. Cologuard is designed to detect DNA alterations and blood released from cancer and precancerous colon lesions and has been proven to find 92 percent of colorectal cancers in average risk patients with 87 percent specificity using only a single sample. Cologuard does not require medication, dietary restrictions or bowel preparation prior to taking the test.

The ACS’ updated information regarding Cologuard is based on ACS’ inclusion of Exact Sciences’ first stool DNA test among the recommended options for colorectal cancer screening in 2008, and the recent availability of the new test. These updated guidelines mark a pivotal benchmark in providing patients and clinicians with information and access to this accurate and convenient colorectal cancer screening option.

Leave a Reply

Your email address will not be published. Required fields are marked *